GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) has earned a consensus rating of "Hold" from the six research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The

Grail (GRAL) shares tumbled almost 50% on Friday after its three-year cancer screening trial missed its main goal, a setback for the blood test maker.The trial

Grail's stock was the Nasdaq's biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C.

The trial was designed to demonstrate a statistically significant reduction in Stage III and Stage IV disease, but the primary endpoint wasn't met. It's possible that the follow-up data will prove more statistically significant.

The major stock indexes rose on Friday morning after the Supreme Court struck down the sweeping global tariffs implemented by President Trump last year, a major setback for the president's signature economic policy.

Biotech stock Grail Inc (NASDAQ:GRAL) is taking a nosedive today, brushing off better-than-expected fourth-quarter results after the company's three-year cancer screening trial failed to meet its main goal.

Stock futures are lower after fourth-quarter GDP badly missed estimates

Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker.

Stock News Oil climbs on Iran risk: Crude headed for its first weekly gain in three weeks as tensions rose over potential U.S. strikes on Iran and possible Stra